CompoAtlas

Colpropur Ostéoarticulaire Fraise

Food supplement declared in France, declaration No 2022-12-949, decision dated 16 December 2022

Colpropur Ostéoarticulaire Fraise, from PROTEIN SA, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Boswellia serrata 50 mg per day, Magnesium, Manganese, Vitamin C, Vitamin D. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
Colpropur
Food business operator placing the product on the market
PROTEIN SA
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Powder
Daily dose
13,6 grammes
Directions for use
prendre 1 dose de 13,6 grammes par jour via doseur intégré
Not recommended (according to the manufacturer)
Kidney failure, Kidney disease, Liver problems
Objectives stated by the manufacturer (these are not authorised claims)
Joints, Hair and nails, Bones, Skin, Oral health
Flavourings
Fraise

Declaration 336350, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Boswellia serrata Roxb. ex Colebr.Gomme résineOléorésine et gomme-oléorésine50 mg

Other active ingredients

NamePer day
Collagène hydrolysénot declared
Méthylsulfonate de méthanenot declared
Hydroxyapatite de calciumnot declared
Glycinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
magnesium salts of citric acidMagnesium250 mg300 mg
manganese citrateManganese8 mg (safe level)3.5 mg
calcium-L-ascorbateVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
PhylloquinoneVitamin Kno limit (insufficient data)dose annulled by the French Council of State in 2011
zinc gluconateZinc25 mg15 mg

Additives

E960, E415

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Les personnes qui nécessitent un régime restreint en protéines (insuffisance rénale ou hépatique très grave) doivent prendre ce produit sous surveillance médicale.Ne convient pas aux Phénylcétonuriques ni aux intolérants au Magnésium.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Collagène hydrolysé
    Read the warning, when it applies and the studies cited

    Hydrolyzed Collagen

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Applies to products providing more than 2.8 g hydrolyzed collagen, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Shils et al. 2006; Goldman and Ausiello 2004).

    Sources cited by Health Canada (2)
    • Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.
    • Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern Nutrition in Health and Disease, 10th edition. Philadelphia (PA): Lippincott Williams and Wilkins, 2006.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Moskowitz 2000).

    Sources cited by Health Canada (1)
    • Moskowitz RW. Role of collagen hydrolysate in bone and joint disease. Seminars in Arthritis and Rheumatism 2000;30(2):87-99. PubMed Randomised trial

    Health Canada monograph dated 28 March 2024

  • Méthylsulfonate de méthane
    Read the warning, when it applies and the studies cited

    MSM

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Kim et al. 2005).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Colpropur

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Colpropur Ostéoarticulaire Fraise: composition and regulation”, https://compoatlas.com/en/supplements/products/336350-colpropur-osteoarticulaire-fraise, updated 15 November 2026.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line